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Data are accumulating to show that the natural history of human immunodeficiency virus type 1 (HIV-1) in chimpanzees
closely reproduces that in humans and is influenced by biologic properties of the infecting HIV-1 strain. To determine the
distribution and relative amounts of HIV-1, proviral DNA in multiple tissues from a chimpanzee euthanized because of an
abdominal tumor and kidney failure was quantified by nested PCR limiting-dilution assays. At death, 21 months after infection
with HIV-1JC499, this animal had a CD4
1 T-cell count of 268 and 1.7 3 105 copies of virion RNA/ml of plasma. The highest
proviral burdens were in peripheral lymph nodes and blood, followed by lung, colon, and spleen; values ranged from 130 to
3350 proviral copies/mg DNA (equivalent to DNA in 150,000 cells). The lowest levels of virus were in the spinal cord, brain,
and cecum (0.3 to 2.5 copies/mg DNA), with all other tissues harboring intermediate levels (6.8 to 114 copies/mg DNA). Viral
burdens in all tissues were comparable to or greater than those reported for HIV-1-infected humans in all stages of disease.
Immunohistochemistry for HIV-1 p24 Gag antigen revealed (i) trapping of HIV-1 on follicular dendritic cells in lymph node
germinal centers and (ii) virus in the brain, where it was localized primarily to capillary endothelial cells in the cerebral cortex.
Analysis of the genetic diversity of the Env V3 loop in tissues indicated that there was no apparent compartmentalization of
HIV-1 variants. Of interest, in 83 of 94 (88.3%) clones sequenced, the unique GYGR motif at the tip of the V3 loop of HIV-1JC499
had reverted to the more common GPGR. The results support the conclusion that HIV-1 has the potential to maintain high
viral burdens in chimpanzees and to disseminate to most organs, including the central nervous system. The use of the
chimpanzee model with HIV-1JC499 (or related strains) in vaccine efficacy studies should prove valuable, especially when
assessing protection against disease. Furthermore, comparison of both replicative properties of HIV-1JC499 with SIVcpz strains
and immune responses of chimpanzees infected with these viruses might provide new information about HIV pathogenesis.
b© 2000 Academic Press
INTRODUCTION
In addition to humans, chimpanzees can be infected
by parenteral and mucosal routes with multiple strains
and subtypes of human immunodeficiency virus type 1
(HIV-1) (Barre-Sinoussi et al., 1997; Bogers et al., 1998;
Fultz et al., 1986a,b, 1999; Girard et al., 1998; Johnson et
al., 1993; Morrow et al., 1989; Nara et al., 1987; Peeters et
l., 1995; Shibata et al., 1995). Although the majority of
IV-1-infected chimpanzees remain asymptomatic up to
2 or more years after infection, some animals have
xhibited evidence of HIV-1 disease, specifically loss of
D41 T cells and increased levels of spontaneous lym-
hocyte apoptosis (Davis et al., 1998); one chimpanzee,
-499, died of AIDS (Novembre et al., 1997). HIV-1 strains
erived from C-499 virus isolates appear to be more
apidly pathogenic for chimpanzees than HIV-1 strains
sed in earlier studies (Davis et al., 1998; Johnson et al.,
993; Morrow et al., 1989; Novembre et al., 1997). Since
ome chimpanzees infected with other HIV-1 strains for
or more years are now experiencing increased viral1 To whom reprint requests should be addressed. Fax: 205-975-6788.
59urdens and decreased numbers of CD41 T cells (P.N.F.,
unpublished data), it appears that in this species the
time from infection to development of AIDS may be com-
parable to or slightly longer than that for humans (ap-
proximately 10 years for 50% of infected humans to de-
velop AIDS) (Fauci, 1996).
Previously, HIV-1-infected chimpanzees were not consid-
ered good models for infected humans because it was
believed that these animals did not support efficient repli-
cation of HIV-1 or develop AIDS. Some inaccuracies asso-
ciated with HIV-1 infection of chimpanzees stem from very
early studies that continue to be cited in lieu of more recent
ones which demonstrate that the earlier studies are no
longer valid (Fultz et al., 1986b; Goudsmit et al., 1987; Mor-
row et al., 1989; Nara et al., 1989). These early studies were
done before it was even known that the median time from
HIV-1 infection to AIDS for humans was about 10 years
(Fauci, 1996). Reasons proposed for why most chimpan-
zees have not developed disease include the inability of
HIV-1 to replicate in chimpanzee macrophages (Gendel-
man et al., 1991; Nara et al., 1989; Schuitemaker et al., 1993);
failure of HIV-1 to infect the central nervous system (CNS) of
chimpanzees (Goudsmit et al., 1987; Grimaldi et al., 1996);
0042-6822/00 $35.00
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I ET Afailure of the virus to establish persistently high viral bur-
dens (Johnson et al., 1993; Morrow et al., 1989; Nara et al.,
989); no trapping of HIV-1 on follicular dendritic cells in
erminal centers of lymph nodes (Koopman et al., 1999);
nd little evidence of immune hyperactivation, including
poptosis (Gougeon et al., 1997; Heeney et al., 1993). How-
ever, previous evaluations of chimpanzees infected with
some HIV-1 strains have shown that most of these assump-
tions are false (Davis et al., 1998; Gendelman et al., 1991;
Novembre et al., 1997; Shibata et al., 1995). Available data
illustrate that some HIV-1 strains are more pathogenic for
chimpanzees than others, just as it has been shown that
some strains are relatively apathogenic in humans, vis-
a`-vis long-term nonprogressors (Cao et al., 1995; Pantaleo
et al., 1995). In addition, animals housed in quarantine are
not exposed to everyday events, such as injuries and inter-
current infections, that are known to activate the immune
system, resulting in increased HIV-1 replication (Donovan
et al., 1996; Garrait et al., 1997; Goletti et al., 1996; Ostrowski
et al., 1998; Sulkowski et al., 1998). At least two studies have
shown that viral burdens in HIV-1-infected chimpanzees
can be increased transiently by vaccination or other meth-
ods of immune stimulation (Fultz et al., 1992; Shibata et al.,
1997). That HIV-1-infected chimpanzees can develop signs
of AIDS-related disease demonstrates that this species is
not inherently resistant to pathogenic effects of HIV-1 and
increases the value of this animal model, especially for
testing candidate HIV-1 vaccines for efficacy.
We previously reported on infection of two chimpanzees
with a strain of HIV-1 (designated JC499), which was iso-
lated from chimpanzee C-499’s peripheral blood mononu-
clear cells (PBMC) (Davis et al., 1998). Infection of both
animals was characterized by persistently high levels of
virion RNA in plasma, gradual loss of CD41 lymphocytes,
ncreased T-cell apoptosis, and immune hyperactivation.
ne of these animals, C-166, was euthanized 21 months
fter cervical inoculation of HIV-1JC499 because of kidney
failure resulting from the presence of a large abdominal
mass which, upon histopathologic examination, was diag-
nosed as a uterine stromal carcinosarcoma, not directly
related to HIV-1-infection. However, this death provided an
opportunity to define HIV-1 viral burden in multiple tissues
from C-166 after only 21 months of infection and before
severe AIDS-defining conditions developed. Here we report
an analysis of the tissue distribution of HIV-1 proviral DNA
and p24 Gag antigen, quantification of proviral DNA in
multiple lymphoid and nonlymphoid tissues, and diversifi-
cation of the Env V3 loop.
RESULTS
Clinical status of C-166
The virologic and hematologic status of C-166 during
the first 15 months of infection before overt clinical dis-
60 WEease became evident has been reported (Davis et al.,
1998). To summarize, within 6 weeks of inoculation of
t
aC-166 with HIV-1JC499, CD4
1 T-cell percentages and ab-
solute numbers and CD4:CD8 ratios began a gradual
decline with concomitant increases in CD81 T cells. After
reaching a maximum of 5 3 106 RNA copies/ml of
lasma at 4 to 6 weeks, plasma viremia fluctuated be-
ween 5.6 3 104 and 4.7 3 105 copies/ml. At the time of
uthanasia, the virion RNA level was 1.7 3 105 copies/ml
of plasma, and the numbers of CD41 and CD81 lympho-
cytes in peripheral blood were 268 and 2059 cells/ml
lood, respectively, for a CD4:CD8 ratio of 0.13. Such a
ow ratio and number of CD41 T cells were indicative of
mmunosuppression. In addition, a relatively high per-
entage of lymphocytes in PBMC, bone marrow, and
esenteric lymph node expressed HLA-DR, indicating
ellular activation (Table 1).
C-166 was euthanized at 21 months after cervical in-
culation because of chronic anemia and elevated blood
rea nitrogen and creatinine levels, indicative of kidney
ailure. Necropsy revealed a large (30 3 15 3 10 cm) firm
ass in the area of the uterus and extensive adhesions
overing all organs in the lower two quadrants of the
bdomen. The left kidney was significantly smaller than
xpected, and on palpation a large cavity was tangible in
ts center. In both kidneys the parenchyma was pale and
irm and had multiple thin, white rays extending from the
urface of the kidneys to the pelvis.
The large abdominal mass was diagnosed as an un-
ifferentiated mixed-cell stromal carcinosarcoma, com-
osed of malignant epithelial cells, neoplastic stromal
ells, and fibrous connective tissue. It also contained
esenchymal components foreign to the uterus, such as
triated muscle, neural cells, and what appeared to be
igestive tract epithelium. Approximately 13 months be-
ore euthanasia, exploratory surgery on C-166 revealed
ysts, which were adherent to the bladder, bowel, and
bdominal wall and could not be removed. At that time
TABLE 1
Hematologic Status of Chimpanzee C-166 at Death
Tissue
Lymphocyte subset (%)a
CD41 DR1CD41 CD81 DR1CD81 CD201
PBMC 11.3 33.1 86.9 10.1 9.9
Bone marrow 11.5 36.5 66.8 28.1 24.0
Mes LN 25.7 8.6 51.1 52.8 30.4
a Values shown are either percentages of total lymphocytes in blood
PBMC) or percentages of total mononuclear cells in single-cell sus-
ensions (bone marrow, Mes LN [mesenteric lymph node]). DR1 cells
ndicate the percentages of each lymphocyte subset that expresses
LA-DR antigens. Percentages of HLA-DR1 CD41 and CD81 cells in
peripheral blood of C-166 at time of inoculation were 6.2 and 8.7%,
respectively.
L.he uterus did not appear to be pathological, and the
nimal recovered from surgery.
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OF HCellular distribution of HIV-1 in vivo
HIV-1-infected cells in tissues were identified by immu-
nohistochemical detection of p24 Gag antigen (Table 2). In
lymph nodes, the greatest amount of p24 Gag antigen was
observed in germinal centers in a pattern consistent with
extracellular virions captured on the surface of follicular
dendritic cells (Fig. 1A). Scattered individual p24 Gag-ex-
pressing lymphocytes also were found in the paracortex of
lymph nodes, which is populated primarily with T cells (not
shown). Examination of the kidney revealed prominent lym-
phocytic infiltrates into the parenchyma, with formation of
lymphoid follicles adjacent to tubules in the cortex. An
occasional p24 Gag-expressing cell was found in areas of
lymphocytic infiltration, but they did not always have lym-
phocyte morphology (Fig. 1B). Cells expressing HIV-1 p24
Gag also were detected in the colon and cecum. In colon
tissue, p24 Gag was detected in both lamina propria lym-
phocytes (Fig. 1C) and intraepithelial lymphocytes (IEL) (not
shown). In the cecum, which had multiple large lymphoid
nodules, p24 Gag was detected only in IEL (Fig. 1D). Of
particular interest was the finding that in the brain HIV-1-
infected cells appeared to be restricted primarily to capil-
lary endothelial cells in the cerebral cortex (Fig. 1F). A
similar granular pattern along the lumen of capillaries has
been reported in the brains of HIV-infected humans (Ward
et al., 1987). Scattered p24 antigen-expressing macro-
phage-like cells also were observed in the brain paren-
chyma (not shown).
Quantification of proviral load in different tissues
The number of proviral copies in 1 mg of DNA from
arious tissues was determined by PCR-based limiting
ilution assays (PLDA), initially using PCR primers that
pecifically amplified the gp120env V3 region of HIV-1JC499.
Depending on the number of proviruses in a DNA sam-
TABLE 2
HIV-1 p24 Gag Antigen in Various Tissues
Tissue p24 Gaga Commentsb
Axillary lymph node 111 Extracellular, in germinal centers
1 T cells in paracortex
Cerebellum 2
Cerebral cortex 11 Endothelial cells
1 Macrophage-like cells
Spinal cord 2
Kidney 1 Lymphocytes in parenchyma
Colon 11 LPL, IEL
Cecum 1 IEL
a Relative amounts of p24 Gag antigen, ranging from none detectable
2) to frequent (111) detection of antigen-positive cells or areas.
b Types of cells in and/or region of tissues containing p24 Gag. LPL,
lamina propria lymphocytes; IEL, intraepithelial lymphocytes.
TISSUE DISTRIBUTIONple, either 1:2 or 1:5 serial dilutions were done. To com-
pare results obtained using the two dilution series, one
h
vDNA sample (duodenum) was quantified both ways. The
1:2 and 1:5 dilution series gave copy numbers of 58.4 (6
33.5) and 61.2 (6 42.6), respectively, thus demonstrating
that the results were comparable. Proviral DNA was
found in all peripheral lymphoid tissues, liver, lung, kid-
ney, gastrointestinal tract, and CNS, with concentrations
of provirus ranging from none in the cerebellum to 3350
copies/mg cellular DNA in the cervical lymph node (Table
). The lowest levels of provirus (less than 1 copy/mg
DNA) were found in the cerebral cortex and lumbar
spinal cord. Although 1 to 4 mg of cellular genomic DNA
rom the cerebellum was used in 16 independent PCRs,
ll PCRs were negative; this tissue sample was the only
ne in which no proviruses were detected. In lymphoid
issues with the highest copy numbers, as many as 1 in
pproximately 50 cells were harboring proviral DNA.
To determine whether equivalent amounts of proviral
NA would be obtained using primers specific for other
egions of the HIV-1 genome, PLDA were performed on
epresentative tissues using primers that amplified the
2-V5 region of gp120env and the p17gag gene (Table 4).
The correlation coefficient for values obtained using the
V3 versus the C2-V5 env primers was 0.9955 (P ,
.0001), the V3 env versus the p17gag primers was 0.920
P 5 0.0268), and the C2-V5 env versus the p17gag
primers was 0.9971 (P 5 0.003). These results indicated
that use of strain-specific V3 primers to quantify proviral
copy numbers was sensitive and accurate.
Sequence variation in the V3 region
Sequence analysis of 94 PCR amplification products of
the V3 region from lymphoid and nonlymphoid tissues
revealed two major and multiple minor variants. At least
one of the two major species was found in each tissue
(Fig. 2). One major V3 variant was represented by 18
clones which contained one change from Y (tyrosine) to
P (proline) at residue 18, when compared to the V3
consensus sequence for HIV-1JC499 (Wei and Fultz, 1998).
he second major variant was represented by 46 clones
ith the same Y to P change at position 18 and, in
ddition, a change from Q (glutamine) to K (lysine) at
osition 33. One or both of these V3 sequences, desig-
ated variants 18P and 18P/33K, were found in provi-
uses throughout the body. While both major variants
ere in several tissues, together they were the predom-
nant sequences in only PBMC, bone marrow, cervical
ymph node, and lung, all of which contain lymphoid
issue. Of those tissues containing only one of the major
equences, the 18P variant was in spleen (1 of 2 clones)
nd thoracic spinal cord (4 of 9 clones). The 18P/33K
ariant was the only major species in the cervical spinal
ord (9 of 11 clones), kidney (2 of 4 clones), jejunum (4 of
clones), and rectum (11 of 11 clones). It is possible,
61IV IN CHIMPANZEESowever, that in those tissues where only one major
ariant was detected, failure to detect the second one
ions w
agnificwas an artifact of the low number of clones sequenced.
With the exception of the 18P and 18P/33K variants, and
three other V3 sequences, each represented twice, all
other V3 sequences were unique. The greatest diversity
in the V3 loop was found in the liver; of 14 clones
sequenced, 10 sequences were represented only once.
Surprisingly, only 1 of 94 proviruses encoded a prema-
ture stop codon in the V3 region.
To determine whether there was a difference in overall
diversity of the V3 loops in lymphoid versus nonlymphoid
tissue, we compared the number of different V3 amino
acid sequences in these compartments. In peripheral
FIG. 1. Immunohistochemical analysis of HIV-1 p24 Gag antigens in t
in axillary lymph node. (B) Right kidney; parenchyma with a single infec
propria lymphocyte. (D) Cecum, p24 Gag antigen-positive intraepithel
incubated with the secondary antibody only. (F) Cerebral cortex; p24 Ga
in E and F were adjacent sections from the same tissue block. All sect
(B), which was counterstained with hemotoxylin and eosin. Original m
62 WEand mucosal lymphoid versus nonlymphoid (CNS, liver,
and kidney) tissues, the frequencies of unique V3 se-
G
(quences differed: there were 11 distinct among 50 (0.22)
total sequences from lymphoid tissue compared with 19
distinct among 44 (0.32) total sequences from nonlym-
phoid tissue. Considering only the CNS, 9 of 26 (0.35)
variant proviruses were detected. As indicated above,
the greatest diversity in the V3 loop was in the liver
where 11 of the 14 (0.786) clones were unique. However,
the mean evolutionary distance (0.0217) between all V3
sequences found in lymphoid tissue differed little from
the mean distance (0.0275) between all sequences found
in nonlymphoid tissues.
An unusual feature of HIV-1JC499 is that it encodes a
amples obtained at death from chimpanzee C-166. (A) Germinal center
among infiltrating lymphocytes. (C) Colon; p24 Gag-expressing lamina
hocyte. (E) Capillary in the cerebral cortex; negative control section
en in capillary endothelial cells and perivascular lymphocytes. Tissues
ere counterstained with methyl green with the exception of the kidney
ations were 3100 (A), 3400 (B, C, E, and F), and 31000 (D).
L.issue s
ted cell
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I ET AYGR instead of a GPGR motif at the tip of the V3 loop
Wei and Fultz, 1998). GYGR was the only motif found in
capproxthe JC499 virus stock used to inoculate chimpanzee
C-166. During the 21 months of infection, most of the
proviruses with the GYGR motif were replaced by GPGR
variants. HIV-1 proviral DNA encoding GYGR became the
minor population (11 of 94 clones), seen only in PBMC (1
of 12 clones), thoracic spinal cord (4 of 9 clones), and
liver (6 of 14 clones); proviruses with the GPGR motif
were found in all tissues evaluated.
DISCUSSION
The importance of chimpanzees to HIV-1 research has
been questioned because of the perceived failure of this
T
Proviral DNA Burden in Tissues from C-166
Compartment Tissue
Peripheral lymphoid PBMC
Bone marrow
Spleen
Cervical lymph node
Mucosal lymphoid Lung
Duodenum
Jejunum
Ileum
Cecum
Colon
Rectum
Central nervous system Cerebral cortex
Cerebellum
Cervical spinal cord
Thoracic spinal cord
Lumbar spinal cord
Nonlymphoid Kidney
Liver
a Number of proviral copies in 1 mg of cellular DNA. Copy numbers w
entral nervous system tissues, for which copy numbers were determ
b The least amount of DNA needed to obtain a positive PCR.
c Conversion of the minimal amount of DNA for positive PCRs to an
equivalent to DNA from 1.5 3 105 cells.
T
Proviral DNA Copy Numbers Obtained Using PCR Pr
Amplified
region
No
Peripheral lymphoid tissue
PBMC Spleen
Cervical
lymph node
Env V3 505 (223) 130 (38.0) 3350 (1860)
Env C2-V5 227 (81.3) 60.9 (42.3) 965 (294)
p17 Gag 227 (81.3) 72.8 (338) NDb
TISSUE DISTRIBUTIONa Number of copies in 1 mg cellular DNA, determined by 1:5 serial PLDA.
b ND, not done.species to develop an AIDS-like disease in association
with experimental HIV-1 or natural SIVcpz infections. Ap-
parent differences between chimpanzees and humans
that were thought to contribute to the observed lack of
disease included viral burden, presence of virus in the
CNS, immune cell activation, and replication in macro-
phages. Several of these misconceptions were based on
results obtained within only 1 or 2 years after experimen-
tal infections were established, while others arose from
the use of HIV-1 strains that replicated poorly in chim-
panzees. However, substantial data which show that
chimpanzees can develop hematologic and immunologic
C499-Specific Primers in the Env V3 Region
No. of copiesa
(standard error)
DNA required for 1 PCR
ngb Cell equivalentsc
505 (223) 0.32 48
78 (37.8) 1.6 240
130 (38) 1.6 240
3350 (1860) 0.32 48
240 (82.5) 0.32 48
61.2 (43.6) 8 1200
114 (76.4) 8 1200
22.6 (15.2) 40 6000
2.5 (0.96) 62.5 9380
207 (146) 8 1200
114 (76.4) 8 1200
0.30 (0.11) 2000 300,000
0
1.67 (0.59) 250 37,500
1.59 (0.42) 250 37,500
0.08 (0.06) 1000 150,000
22.7 (15.3) 40 6000
6.76 (1.86) 125 18,800
termined using 1:5 serial limiting dilutions except for cecum, liver, and
ing 1:2 serial limiting dilutions.
imation of the number of cells required; 1 mg DNA is assumed to be
hat Amplify Different Regions of the HIV-1 Genome
iesa (standard error)
Mucosal lymphoid tissue Nonlymphoid tissue
Duodenum Jejunum Liver Kidney
61.2 (42.6) 144 (76.4) 6.76 (1.86) 22.7 (15.3)
99.7 (50.2) ND 2.31 (1.0) 32.5 (17.4)
113 (76.4) 61.8 (43.1) ND 61.8 (43.1)
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ease and AIDS are now available.
The present study shows that a chimpanzee, C-166,
infected for 21 months with HIV-1JC499 maintained high
virus burdens in both peripheral and mucosal lymphoid
tissues throughout infection. Furthermore, at death due
to a massive abdominal tumor and kidney failure, HIV-1
was detected by nested PCR and/or immunohistochem-
istry in all tissues, including the CNS, albeit at low levels.
Comparisons of proviral copy numbers in various tissues
obtained by biopsy or at autopsy from HIV-1-infected
humans with copy numbers from chimpanzee C-166 re-
vealed equivalent levels of virus (Table 5). Among both
symptomatic and asymptomatic HIV-1-infected humans,
there was broad variation in proviral copy numbers. Even
among symptomatic adults, HIV-1 proviral DNA in 1 mg of
FIG. 2. Translated V3 amino acid sequences of HIV-1 proviruses in
tissues from chimpanzee C-166. All sequences were compared with
the V3 consensus sequence of clones obtained from C-499’s PBMC
(Wei and Fultz, 1998). A period indicates identity with the consensus
sequence, and an asterisk indicates a premature stop codon. n, Num-
ber of clones representing a particular sequence. The circle and star to
the right of the sequences identify the major variants 18P and 18P/33K,
respectively.
64 WEgenomic DNA ranged from 0 to 44,000 in PBMC, from 0
to 406 in lung, and from 0.3 to 7900 copies in spinal cord
G
c(Bell et al., 1993; Cao et al., 1992; Donaldson et al., 1994;
Donovan et al., 1996; Fackler et al., 1998; Itescu et al.,
1994; Sei et al., 1994). In general, the lowest levels of
HIV-1 were found in the CNS, particularly in the cerebel-
lum, of both chimpanzee C-166 and humans.
The above results reflect viral burdens in only one
chimpanzee; however, we have quantified proviral DNA
in PBMC and lymph node from another chimpanzee
inoculated with HIV-1JC499 at the same time as C-166
Davis et al., 1998). Near the same time that C-166 died,
this second asymptomatic animal had approximately 50
and 1200 proviral copies/1 mg DNA in PBMC and lymph
node, respectively. Although this second animal had
about 5- to 10-fold fewer proviral copies in PBMC than
C-166, this result could merely reflect normal fluctuations
in viral load. However, HIV-1 proviral DNA levels in pe-
ripheral lymph nodes of these two chimpanzees were
comparable. All tissues available from other HIV-1-in-
fected chimpanzees that had died previously were for-
malin-fixed, which substantially lowers the sensitivity of
DNA to PCR amplification and would render any results
unreliable (Davison et al., 1996). Although it is possible
that the tumor influenced levels of virus replication, it is
more likely that immunosuppression due to HIV-1JC499
facilitated tumor growth. As we reported previously
(Davis et al., 1998), high viral burdens were established
during the acute phase of HIV-1JC499 infection in both
-166 and a second chimpanzee inoculated at the same
ime. Furthermore, both animals experienced gradual
eclines in CD41 T cells within 6 weeks of inoculation.
In the cerebral cortex of C-166, HIV-1 p24 Gag was
seen primarily in capillary endothelial cells, which are
known to be sites of HIV-1 and SIV replication in humans
and macaques, respectively (An et al., 1999a,b; Lackner
t al., 1991; Mankowski et al., 1994; Moses et al., 1993;
ard et al., 1987; Wiley et al., 1986). HIV-1 has also been
hown to infect human endothelial cells in liver sinusoids
Steffan et al., 1992). Although capillary endothelial cells
o not express CD4, these cells do express the primate
entivirus coreceptors CCR5 and CXCR4 (Edinger et al.,
997; Lavi et al., 1997), which facilitate CD4-independent
nfection (Endres et al., 1996; Lavi et al., 1997). In addition
o capillary endothelial cells, we also observed widely
cattered macrophage-like cells expressing p24 Gag.
lthough these cells appeared to be macrophages mor-
hologically, it is possible that they were microglia or
nother cell resident in the CNS. Both infiltrating macro-
hages and microglial cells have been shown to be
nfected with HIV-1 in human brains (Donaldson et al.,
994; Koenig et al., 1986; Korber et al., 1994; Wiley et al.,
986). In addition to capillary endothelial cells, a variety
f cells in the brain express HIV-1 coreceptors CCR3,
CR5, and CXCR4 (He et al., 1997; Lavi et al., 1997).
With the exception of the brain, relative amounts of p24
L.ag and proviral copy numbers for all tissues were
onsistent. Since the distribution of HIV-1-infected endo-
u
m
ferenc
c 105 celthelial cells in the brain was not homogeneous, it is likely
that the discordance between the low proviral copy num-
ber and the amount of p24 Gag antigen detected in the
cerebral cortex was due to differences in the sites from
which the tissue samples for the two assays were ob-
tained. However, the data unambiguously show that
HIV-1 can infect the CNS of chimpanzees. One difference
between our study and previous ones which failed to
detect HIV-1 in the CNS of infected chimpanzees is that
in the latter only cerebrospinal fluid was tested
(Goudsmit et al., 1987; Grimaldi et al., 1996).
By nested PLDA, viral burdens in most tissues from
C-166 were comparable to those found in biopsies and in
tissue samples obtained at autopsy from both symptom-
atic and asymptomatic HIV-infected humans, demon-
strating the similarities between HIV-1-infected humans
and chimpanzees relative to virus burden and dissemi-
nation throughout the body. As in symptomatic humans,
C-166 had extensive virus trapping by follicular dendritic
cells in germinal centers of lymph nodes. Such trapping
was reported previously only for chimpanzee C-499 that
died of AIDS (Novembre et al., 1997). Lymphoid hyper-
plasia in lymph nodes, in association with large numbers
T
Comparison of Proviral Copy Numbersa in Tissue
Tissue
Chimpanzee
C-166 Presymptomatic
PBMC 505 30.7–426
1.05–4.05
Spleen 130 42.6–221
Lymph node 3350 2.10–592
Lung 240 0–3.45
Duodenum 61.2
Colon 207 0–6.90
Cerebral cortex 0.30 0–0.33
0–4.05
Cerebellum 0
Thoracic spinal cord 1.59 0.33–2.70
Kidney 22.7
Liver 6.67
a All copy numbers are expressed as copies/1 mg DNA. In some re
onverted to mg DNA assuming that 1 mg DNA is equivalent to 1.5 3
TISSUE DISTRIBUTIONof CD41 and CD81 lymphocytes expressing HLA-DR
antigens (Table 1), indicated that chimpanzee C-166 wasexperiencing abnormal levels of cellular activation.
These findings are consistent with our earlier study
showing that PBMC from C-166 and two other HIV-1-
infected chimpanzees exhibited increased levels of
apoptosis ex vivo in the absence of exogenous mitogenic
stimulation (Davis et al., 1998).
Although the genetic basis for the apparent increased
pathogenicity of HIV-1JC499 is not known, this strain has a
nique motif at the tip of the V3 loop in Env. Instead of the
ore prevalent GPGR motif, HIVJC499 encodes a GYGR. Of
2588 V3 loop sequences from all known HIV-1 subtypes,
as well as from group O, only one other strain (from
subtype B) encodes a tyrosine (Y) at this position (Korber
et al., 1998). That the GYGR was found in only 11 of 94
(11.7%) sequences obtained from multiple tissues from
C-166 after 21 months of infection suggests that a ty-
rosine residue is not favored at this position. Because of
the opposite hydrophobicities of tyrosine and proline, the
conformation of V3 loops containing GYGR or GPGR may
differ. Residue 33 was the only other amino acid that was
changed in a majority of the V3 loop sequences identi-
fied in C-166 proviruses; in 60 of 94 (63.8%) sequences,
the glutamine (Q) in the consensus sequence for the
HIV-1-Infected Humans and Chimpanzee C-166
Children Ref.Symptomatic
0–28.5 Donaldson et al., 1994
4.05–28.6 Bell et al., 1993
0–22,500 Cao et al., 1992
600–44,000 Fackler et al., 1998
161–296 Donaldson et al., 1994
98.8 496 Sei et al., 1994
7.35–1800 Donaldson et al., 1994
453 1630 Sei et al., 1994
0–406 Donaldson et al., 1994
10.9 42.5 Sei et al., 1994
450–750 Itescu et al., 1994
975–27,000 Donovan et al., 1996
0–790 Donaldson et al., 1994
10.6 140 Sei et al., 1994
450–5000 Fackler et al., 1998
16–2360 Donaldson et al., 1994
0 37.9 Sei et al., 1994
4.05–405 Bell et al., 1993
0 2.9 Sei et al., 1994
6.90–7900 Donaldson et al., 1994
0.3 14.5 Sei et al., 1994
5.6 13.4 Sei et al., 1994
0–4050 Cao et al., 1992
4.4 10.3 Sei et al., 1994
es copy numbers were given as copies/106 cells; these values were
ls.
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s from
Adults
OF HJC499 quasispecies had changed to a lysine (K). This
mutation resulted in an increase in the net positive
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I ET Acharge of the V3 loop from 10 to 11. Such high numbers
of positive charges in the V3 loop are associated with a
syncytium-inducing (SI) phenotype and an inability to
replicate well in macrophages (Chesebro et al., 1992;
ouchier et al., 1992; Korber et al., 1994). Viruses derived
rom PBMC from the chimpanzee that died of AIDS (C-
99) have an SI phenotype, as does the parental
AI(LAV-1b) strain. However, these viruses also replicate
ell in chimpanzee macrophages, indicating that they
re dual tropic (Gendelman et al., 1991; Mwaengo and
ovembre, 1998). Whether HIV-1JC499 can utilize both the
CR5 and CXCR4 coreceptors has not yet been tested. It
ill be of interest to determine whether the novel ty-
osine in the GYGR motif influences coreceptor usage.
lthough isogenic env clones are being constructed,
heir analysis will be restricted to in vitro studies be-
ause it is not practical to test multiple HIV-1 variants for
athogenicity in chimpanzees.
In the analysis of the V3 loop sequences in various
issues from chimpanzee C-166, we did not detect any
ross compartmentalization or genetic differences in the
issue distribution. There has been suggestive evidence
hat some human tissues, such as mucosa or brain,
electively support replication of macrophage-tropic
IV-1 strains. Whether distinct variants defined by the V3
oop are selected and proliferate in the brain relative to
lood or other tissues appears to vary from one person
o another. Different studies have reported either an
pparent compartmentalization or no differences in V3
equences from blood and CSF isolates (Keys et al.,
993; Korber et al., 1994; Power et al., 1994; van’t Wout et
l., 1998). None of the proviral V3 loops in any tissue from
-166 encoded site-specific amino acids that previously
ere associated with macrophage tropism (Chesebro et
l., 1992; Donaldson et al., 1994; Fouchier et al., 1992;
hioda et al., 1992; Westervelt et al., 1992) or had the
brain “signature sequences” defined by Korber et al.
(1994). C-166’s liver was the only organ in which the
proviral V3 sequences suggested tissue-specific evolu-
tion and limited trafficking.
That chimpanzees infected with HIV-1 strains related
to JC499 can develop high viral burdens and hematologic
and immunologic abnormalities indicative of HIV-1 dis-
ease may be critical for future evaluation of HIV-1 vac-
cines. Consistent with vaccines against other viruses,
such as poliovirus, one can assume that prior immuni-
zation against HIV-1 will not prevent the majority of ex-
posed individuals from becoming infected. Therefore, an
effective vaccine will need to elicit immune responses
that rapidly curtail virus replication and prevent high viral
burdens from being established. If this goal is achieved,
it would have a major impact on disease progression in
individuals and on transmission within a population.
However, since it is projected that volunteers who be-
66 WEcome infected during Phase III HIV-1 vaccine trials will
be given antiviral drugs immediately, it will not be pos- fsible to determine whether the vaccine-induced immune
responses alone would have been sufficient to prevent
or greatly increase the time between infection and dis-
ease. Thus, the only remaining way to evaluate whether
a vaccine is efficacious will be to use the HIV-1 chim-
panzee model. If candidate vaccines elicit some level of
protective immunity, subsequent infections established
in the immunized chimpanzees more than likely would
be analogous to the dormant infections described in
long-term nonprogressors. In the event that latent infec-
tions with HIV-1 strains similar to JC499 are not estab-
lished in immunized and challenged chimpanzees, then
animals with high virus burdens would be prime candi-
dates in which to evaluate novel therapeutic intervention
strategies. In the past, the low viral burdens established
by some HIV-1 strains restricted their use in the HIV-1
chimpanzee model to prophylactic, not therapeutic, stud-
ies (Grob et al., 1997; Schleif et al., 1994).
MATERIALS AND METHODS
Chimpanzee
Chimpanzee C-166 was inoculated with approximately
600 TCID50 of HIV-1JC499 by the cervical route, as de-
cribed (Girard et al., 1998). Briefly, the inoculum was
xpelled into the endocervical canal with a short piece of
ubing mounted on a rigid metal catheter and syringe. A
olposcope was used to ensure correct placement of the
noculum and to prevent trauma to the cervical os. Due to
idney dysfunction and deteriorating health, the animal
as euthanized 21 months after infection by first sedat-
ng it with ketamine hydrochloride, after which an over-
ose of pentabarbitol was administered intravenously. At
ecropsy, tissue samples taken from various organs
ere fixed in formalin and embedded in paraffin, and thin
ections were cut for histopathologic analysis and HIV-1
24 antigen detection. Lymphoid tissues were pro-
essed to generate single-cell suspensions, and frag-
ents of all tissues were cryopreserved for PCR analy-
is. Housing and care of the chimpanzee were provided
ccording to the Animal Welfare Act and standard prac-
ices for the humane care and use of chimpanzees in
iomedical research.
low cytometry
Percentages of lymphocytes were determined with a
ACScaliber flow cytometer (Becton–Dickinson, Moutain
iew, CA), gating on viable lymphocytes according to
orward and side scatter characteristics. Fluorochrome-
abeled monoclonal antibodies specific for human cell
urface antigens (all from Becton–Dickinson) were used
o identify lymphocyte subsets.
mmunohistochemistry
L.Slides of paraffin-embedded tissues were deparaf-
inized, rehydrated, and predigested with proteinase. Af-
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OF Hter quenching endogenous peroxidase activity with hy-
drogen peroxide, slides were incubated with normal rab-
bit serum. Endogenous biotin in tissues was blocked by
avidin/biotin blocking key (Vector Laboratories, Inc., Bur-
lingame, CA). HIV-1 p24 Gag antigen was detected with
a 1:10 dilution of a mouse monoclonal antibody to p24
(Dako Corporation, Carpinteria, CA) as the primary anti-
body and a catalyzed signal-amplification system (Dako)
that employed a rabbit anti-human IgG as the secondary
antibody. As a negative control, an isotype-matched ir-
relevant murine monoclonal antibody was used on adja-
cent sections of all tissues. Sections were counter-
stained with 0.5% methyl green or hematoxylin and eosin.
Quantification of proviral DNA
Genomic DNA was isolated from PBMC, various tissue
samples, and single-cell suspensions of cervical lymph
node and spleen using QIAamp blood and QIAamp tis-
sue kits (Qiagen, Chatsworth, CA). Proviral DNA was
then quantified by nested PCR-based limiting dilution
assays using primers spanning either the env V3 loop,
the C2-V5 region of gp120env, or the p17 region of gag.
The nucleotide sequences of the primers for amplifica-
tion of the C2-V5 fragment (outer primers, C and H; inner
primers, D and F) and the p17 gag gene (outer primers,
P17/1 and P17/4; inner primers, P17/2 and P17/3) were
described previously (Fultz et al., 1997; Wei and Fultz,
1998). To amplify the V3 loop, reverse primers specific for
the JC499 strain were generated and used with forward
primers C and D. The JC499-specific primers were JCII,
59-TCTAGGTCTCCTCCTGAGGACCGG-39, bases 6900 to
6877 of HIV-1JC16 (Mwaengo and Novembre, 1998) (cor-
responding to bases 7331 to 7309 of the HIV-1HXB2 mo-
ecular clone); and JCI, 59-TAGCTATCTGTTTAAAG-
GTTG-39, bases 6830 to 6808 of HIV-1JC16 (bases 7262 to
239 of HIV-1HXB2).
The two-pass strategy employed to estimate proviral
opy numbers consisted of at least two independent
LDA on 1:5 and/or 1:2 serial dilutions of DNA samples
Rodrigo et al., 1997). The first PLDA was a single nested
CR amplification of each fivefold serial dilution, begin-
ing with 1 mg of DNA. If the last positive PCR was at a
1:25 or higher dilution, the second pass consisted of
additional nested PCR replicates of the fivefold serial
dilutions. If the only positive PCRs were with an undiluted
or a 1:5 diluted sample, nested PCR replicates were then
performed with twofold serial dilutions of DNA. If there
were no positive nested PCRs in the first PLDA, then the
second nested PCRs were done with twofold replicates
starting with more than 1 mg DNA. Using the results of
oth sets of replicate nested PCRs, the proviral copy
umbers were determined by using a statistical com-
uter program, termed QUALITY (Rodrigo et al., 1997).
TISSUE DISTRIBUTIONhe P values associated with the x2 values for all PLDA
hat amplified the V3 region ranged from 0.4384 to.9842. To compare proviral copy numbers obtained with
ifferent primer pairs, Pearson’s linear correlation (Instat
.0, GraphPad software) was used.
equence analyses
The PCR products were recovered from agarose gels
ith a QIAquick Gel Extraction kit (Qiagen) and were
ither sequenced directly or were purified and cloned
nto a pCR2.1 vector using a TA Cloning kit (Invitrogen,
an Diego, CA). Amplicons from the highest dilution (i.e.,
ast positive PCR) were assumed to contain one provirus
nd, therefore, were sequenced directly. When only the
ndiluted or the first dilution of DNA was positive, the
mplicons were cloned. Nucleotide sequencing was per-
ormed with a Sequenase v2.0 kit (Amersham Life Sci-
nce, Inc., Cleveland, OH). Alignment of nucleotide and
mino acid sequences was done using MacVector 6.0
oftware (Oxford Molecular Group, Beaverton, CA). The
enetic distances between nucleotide sequences were
etermined using Kimura’s two-parameter method with
he transition/transversion ratio set at 2.0 (program DNA-
IST, PHYLIP 3.572 package).
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